Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure fund (CTIF) experience.

Abbott, Lesleigh S.; Pater, Joseph L.; Friel, Kay; Kato, Diana; Dancey, Janet

doi:10.1200/jco.2014.32.15_suppl.6602

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Trial Prospector, a point‐of‐care application for screening patients for clinical trials, was developed by Case Comprehensive Cancer Center (Cleveland, OH) and was shown to have a positive role for improving clinical trial accrual . Other institutions have tried issuing Clinical Trial Infrastructure Funds, which improved clinical trial accrual by 12%–13% from baseline .…”

Section: Discussionmentioning

confidence: 99%

Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors

et al. 2018

View full text Add to dashboard Cite

Clinical trial completion is critical for new cancer therapies. Premature trial termination or withdrawal is common and impairs progress. This study assessed factors of early terminated/withdrawn oncology trials, focusing on trials with immune checkpoint inhibitors (ICI), and found that poor accrual represents the main cause of early cancer trial termination. Premature termination/withdrawal rate was not significantly lower in immune checkpoint inhibitor trials compared to other trials. The discussion herein is focused on measures taken by the National Cancer Institute and other institutions to improve clinical trial accrual and prevent premature clinical trial discontinuation.

show abstract

Section: Discussionmentioning

confidence: 99%